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umber of clostridial bacteria produce toxins which 
ADP-ribosylate  monomeric  actin.  These  include 
botulinum C2 toxin (2), Clostridiumperfringens iota 
toxin (23, 26), Clostridium spiroforme toxin (20, 27), and an 
ADP-ribosyltransferase produced by Clostridium difficile (21). 
The toxins have turned  out  to be valuable tools for investigating 
the actin cytoskeleton since ADP-ribosylation of  actin blocks 
its polymerization. Furthermore, ADP-ribosylated actin acts 
as a capping protein that binds to the fast-growing barbed end 
of polymerized F-actin to further inhibit polymerization of 
nonmodified actin. This class of newly isolated toxins can be 
used to investigate the dynamic turnover of G- and F-actin in 
living cells. The best studied example of these new toxins is 
botulinum C2 toxin, which is described in this review in more 
detail. 
Botulinum C2 Toxin 
Botulinum C2 toxin, which is produced by various strains of 
Clostridium botulinum types C and D, has been purified to 
apparent homogeneity (16). The binary toxin comprises two 
nonlinked subunits, component I and II, whose pharmaco- 
logical actions depend on their functional communication (8, 
10-12,  14,  15,  17, 22). 
Component II of  botulinum C2 toxin has a molecular mass 
of ~100 kD on SDS-PAGE  (16) and is responsible for the 
binding of the toxin to the eukaryotic cell surface (14). This 
component has to be activated by trypsin treatment to pro- 
duce a binding site for component I (13), an '~72-kI) proteo- 
lytic fragment. It has been reported that this activated com- 
ponent II forms an oligomeric structure with a  molecular 
mass of 365 kD having both hemagglutinating and hemolytic 
activities. The monomer possesses only hemagglutinating 
activity (13).  So far, the nature of the cell surface receptor 
for component II and the mechanism of cell entry of compo- 
nent I is not known. 
The 50-kD component I of botulinum C2 toxin possesses 
ADP-ribosylating activity (25). The protein substrate is non- 
muscle actin (1, 2). The modification  on actin is due to mono- 
ADP-ribosylation since no increase in the molecular mass of 
labeled protein  is observed  during ADP-ribosylation and 
phosphodiesterase  treatment  of  [32P]ADP-ribosylated  actin 
releases labeled 5'-AMP.  The Km of the ADP-ribosylation 
reaction for NAD is 1-5/~M (1) and the pH optimum is be- 
tween pH 7 and 8 using homopolyarginine as the substrate 
(28). As found for other bacterial ADP-ribosyltransferases, 
botulinum C2 toxin possesses glycohydrolase activity and 
splits NAD into ADP-ribose and nicotinamide. 
Other Actin-ADP-ribosylating Toxins 
In addition to botulinum C2 toxin, C. perfringens iota toxin 
(23, 26), C. spiroforme toxin (20, 27), and an ADP-ribosyl- 
transferase from C. difficile (21) (distinct from C. di~icile 
toxins A and B) also ADP-ribosylate actin. These "iota-like" 
toxins  are  binary  in  structure  and  are  immunologically 
closely related to each other representing a subfamily of ac- 
tin-ADP-ribosylating toxins (27, 30). Botulinum C2 toxin is 
not recognized by antibodies raised  against these toxins. 
Moreover, the binding components of the iota-like toxins can 
substitute for each other in their transport ability, whereas 
a botulinum C2 toxin binding component cannot be inter- 
changed with the other toxins (27). Recently, a cell line has 
been described which is apparently sensitive to botulinum 
C2 toxin but not to iota-like toxins, suggesting that different 
cell surface receptors are involved (37). 
ADP-ribosylation of  Actin by Botulinum C2 Toxin 
Both isoforms of nonmuscle actin (fl and 3,) are good sub- 
strates for C2 toxin (33).  Skeletal muscle actin (or) is modi- 
fied by the toxin only to a limited extent (2). Furthermore, 
the substrate of botulinum C2 toxin and of the other toxins 
is monomeric G-actin, not polymerized F-actin. For unknown 
reasons, the ability of purified actin to accept ADP-ribosyla- 
tion declines during storage; and whereas 0.9 mol ADP-ribose 
per mole of  protein can be incorporated into freshly prepared 
actin, this rapidly decreases with time. 2-wk-old actin is usu- 
ally not more than 15-30%  ADP-ribosylated. 
Botulinum C2 toxin ADP-ribosylates nonmuscle actin on 
Arg-177 (33).  Since skeletal muscle actin also has Arg at res- 
idue 177 (31), it has been suggested that the preceding amino 
acid (methionine in skeletal muscle actin; leucine in non- 
muscle actins) is important for ADP-ribosylation. However, 
C. perfringens iota toxin modifies Arg-177 in skeletal muscle 
actin also (32). Thus, the specificity of ADP-ribosylation de- 
pends not only on the type of actin isoform but also on the 
toxin used. 
ADP-ribosylated Actin Behaves Like a Capping 
Protein 
Several  findings  indicate  that  ADP-ribosylation  of  actin 
blocks its ability to polymerize. Botulinum C2 toxin reduces 
the viscosity of polymerized liver actin as measured by the 
falling ball  device (2).  Electron microscopy supports  the 
view that the toxin drastically decreases actin polymerization 
and formation of filaments (1). More recent investigations in- 
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Figure 1.  Model  of the  action  of botulinum  C2  toxin on  the 
microfilament network of cells. By an unknown mechanism, com- 
ponent II (C2II) of the binary botulinum C2 toxin transfers the 
ADP-ribosylating component I (C21) into the cell. ADP-ribosyla- 
tion by the toxin turns actin into a capping protein, which binds to 
the barbed end of filaments to inhibit polymerization. The actin 
concentration is increased by depolymerization at the pointed ends. 
G-actin monomers released are substrates of the toxin. As ADP- 
ribosylated actin loses its ability to polymerize, it will accumulate, 
which finally causes breakdown of the microfilament network. 
dicate that ADP-ribosylated actin inhibits polymerization of 
unmodified actin like a capping protein (34, 36). However, 
ADP-ribosylated actin does not influence elongation at the 
pointed ends of actin filaments that are capped at the barbed 
ends by gelsolin (34). These findings indicate that ADP-ribo- 
sylated actin acts like a barbed end-capping protein. Accord- 
ingly, ADP-ribosylated actin increases the critical concentra- 
tion for actin polymerization from the low value characteristic 
of  the barbed end to the high critical concentration character- 
istic of the pointed ends (18, 35). In contrast to gelsolin, ADP- 
ribosylated actin did not act as a nucleus for formation of new 
actin filaments. The equilibrium constant K for the binding 
of ADP-ribosylated actin to the barbed end ofactin filaments 
is  ,'o108 M -~  (34).  Monomeric  actin  ADP-ribosylated by 
botulinum C2 toxin or iota toxin also has reduced ATPase 
activity (6). 
Botulinum C2 Toxin Is a Cytotoxin 
Injection of both components of botulinum C2 toxin (12 #g) 
into the intestinal loop of mice causes fluid accumulation af- 
ter a delay of 1-2 h (11). The toxic effect is increased by tryp- 
sin treatment of component II. Morphological changes after 
toxin application indicate induction of an acute inflammation 
(15).  Cytoplasmic vacuolation, desquamation,  and  finally 
necrosis of epithelial cells and of the lamina propria occurs. 
Botulinum C2 toxin increases the vascular permeability (12, 
24), an effect observed even when each component of the 
toxin was applied at different times and at separate locations. 
Botulinum C2  toxin causes rounding-up of a  variety of 
types of cells, although cells vary in their sensitivity. Vero 
cells round-up at 0.5 ng/ml botulinum C2 toxin while FL 
(human  amnion)  cells  required  concentrations 200  times 
higher 07). As in studies with ligated intestinal loops, round- 
ing begins in '~1 h, followed by lysis after 24-48 h (17). Y-1 
adrenal cells were shown to withstand the toxin for at least 
24 h, although morphological changes occurred (37). 
A Model for the Cytotoxic Effects of  Botulinum 
C2 Toxin 
For the pathophysiological relevance of actin ADP-ribosyla- 
tion, it was particularly important to establish that modifica- 
tion of actin occurred in intact cells. Treatment of intact cells 
with botulinum C2 toxin or with other actin-modifying toxins 
reduced  or  blocked  subsequent  [32p]ADP-ribosylation  of 
actin in cell lysates (2, 22).  Rounding-up of chicken cells 
correlated with toxin-induced ADP-ribosylation of actin in 
a  time- and concentration-dependent manner. In 32p-loaded 
chicken cells botulinum C2 toxin labeled a 43-kD protein, 
which was identified as actin by binding to a DNase I column 
and subsequent protease mapping (22). ADP-ribosylated ac- 
tin was exclusively found in Triton-soluble but not in Triton- 
insoluble fractions, suggesting that G-actin but not F-actin is 
the substrate of the toxin in intact cells (22). 
Rounding-up induced by botulinum C2 toxin is associated 
with destruction of the microfilament network of intact cells 
(22). After treatment of chicken embryo cells for 3 h with 
botulinum C2 toxin, stress fibers became condensed, short- 
ened, and broken. After 6 h of toxin treatment, stress fibers 
mostly vanished and heaps of material amorphously stained 
by  fluorescein-phalloidin appeared.  At  this  stage at  least 
95 % of cells were alive as determined by trypan blue exclu- 
sion.  The  G-actin  content of toxin-treated fibroblasts  in- 
creased concomitantly with  ADP-ribosylation of actin  (3, 
22).  Together these  findings  indicate  that  botulinum  C2 
toxin-induced treatment of intact cells causes depolymeriza- 
tion of actin filaments. 
From the data available, the following model for the cyto- 
toxic effects of actin ADP-ribosylating toxins has been pro- 
posed (Fig.  1).  It is generally accepted that in nonmuscle 
cells monomeric and polymeric actin are in dynamic equilib- 
rium and their levels are regulated by the transition between 
G- and F-actin and by actin-binding proteins (7, 19). Botuli- 
num C2 toxin and other actin-modifying toxins apparently 
interfere with this equilibrium by ADP-ribosylation of actin. 
The modified actin caps the barbed end of actin filaments 
thereby blocking further polymerization at this end of the 
filaments, while the pointed ends continue depolymerizing. 
The cellular pool of G-actin, which serves as substrate for 
botulinum C2 toxin, increases. As ADP-ribosylated actin is 
not capable of polymerization, the toxin traps actin in its 
monomeric form, which is no longer available for formation 
of microfilament networks. All these events finally cause de- 
struction of the microfilament network. 
ADP-ribosylating Toxins Are Tools to Study 
the Function of  Actin 
Treatment of neutrophils with the toxin blocked random and 
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view that polymerization of actin is involved in cell move- 
ment (29). Like cytochalasin treatment, toxin treatment in- 
creased stimulated, but not basal, superoxide anion produc- 
tion (4, 10), secretion of N-acetylglucosamine and of vitamin 
B~2-binding  protein  from  human  neutrophils  (10).  Treat- 
ment of PC12  cells  at 20°C  with botulinum C2  toxin in- 
creased  the  [3H]noradrenaline  release  stimulated  by  car- 
bachol,  K ÷  depolarization,  and  by  ionophore  A  23187 
1.5-3-fold (8).  Concomitantly, actin was ADP-ribosylated. 
Toxin treatment at 37°C  showed a  biphasic  effect on nor- 
adrenaline release from PCI2 cells which was interpreted as 
an involvement of actin in secretion at more than one site. 
In Y-1  adrenal cells,  botulinum C2 toxin increased steroid 
secretion about twofold (37). B6ttinger et al. (5) reported the 
inhibition of histamine release  from mast cells after treat- 
ment with botulinum C2 toxin. 
Recently,  it has been found that botulinum C2 toxin in- 
hibits electrically  stimulated contractions of guinea pig il- 
eum  longitudinal  smooth  muscle  preparations  (9).  This 
effect  was  most  likely  caused  by  a  direct  toxin action on 
smooth  muscle  cells,  because  Ba2+-induced  contractions 
were also inhibited by botulinum C2 toxin. As botulinum C2 
toxin  ADP-ribosylates  G-actin  but  not  F-actin,  the  latter 
studies indicate that monomeric actin is relevant for smooth 
muscle function and indicate a dynamic transition between 
G- and F-actin, also in smooth muscle cells. The increasing 
number of studies suggest that actin-ADP-ribosylating tox- 
ins are powerful tools for investigating the cellular functions 
of actin. 
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